ISCDx
Commercial- Indications
- Ischemic stroke, Cardioembolic stroke, Large artery atherosclerosis
Company intelligence / Profile preview
Ischemia Care has developed and launched ISCDx, the first blood test able to identify the cause of ischemic stroke by analyzing gene expression patterns in whole blood. The technology leverages next-generation sequencing and microarray data analyzed via machine learning. Clinical results from over 1,400 patients across more than twenty hospitals demonstrated significant support for its ability to differentiate major causes of ischemic strokes. The company has accumulated over 5,000 patient samples supporting a robust pipeline targeting further diagnostic applications in cerebrovascular disease.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ischemia Care.